EA
GTHX

Emerald Advisers’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Emerald Advisers’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-485,954
Closed -$25.4M – 271
2018
Q3 		$25.4M Sell
485,954
-20,470
-4% -$1.12M 0.93% 32
2018
Q2 		$22M Sell
506,424
-195,975
-28% -$8.4M 0.83% 48
2018
Q1 		$26M Sell
702,399
-19,039
-3% -$508K 1.04% 28
2017
Q4 		$14.3M Sell
721,438
-6,995
-1% -$150K 0.55% 72
2017
Q3 		$18.1M Buy
728,433
+17,977
+3% +$332K 0.74% 56
2017
Q2 		$12.4M Buy
+710,456
New +$12.4M 0.52% 80

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Emerald Advisers's GTHX Position: Q4 2018 in Review

Emerald Advisers sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2018, closing a stake of 485,954 shares — an estimated $25.4M sold.

Emerald Advisers first reported a position in GTHX in Q2 2017 and held it in 6 quarters. The position peaked at $26M in Q1 2018. 93 funds tracked by Wall St. Rank hold GTHX as of Q4 2018.

  • Emerald Advisers reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Emerald Advisers sold 485,954 G1 Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $25.4M.
  • Emerald Advisers first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 6 quarters.
  • Emerald Advisers's G1 Therapeutics, Inc. Common Stock position peaked at $26M in Q1 2018.
  • 93 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Emerald Advisers's 13F filing for Q4 2018, filed 30 Jan 2019.